The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma.
 
Ghassan Abou-Alfa
Consulting or Advisory Role - Abbvie; Ability Pharma (I); Agenus (I); Alligator Bioscience (I); Arcus Ventures (I); Astellas Pharma (I); Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Fibrogen (I); Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Moma Therapeutics (I); Neogene Therapeutics (I); Novartis (I); Regeneron (I); Revolution Medicines (I); Roche/Genentech; Servier; Syros Pharmaceuticals (I); Tango Therapeutics (I); Tempus (I); Vector Health; Yiviva
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Beigene (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Yiviva (Inst)
 
Yun Yen
Leadership - Lixte Biotechnology
 
James Harding
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Medicine; Elevar Therapeutics; Exelixis; Jazz Pharmaceuticals; Merck; RayzeBio; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Jazz Pharmaceuticals (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Tvardi Therapeutics (Inst); yivvia (Inst); Zymeworks (Inst)
 
Jacqueline Whang-Peng
No Relationships to Disclose
 
Yuankai Shi
No Relationships to Disclose
 
Man Fung Yuen
Honoraria - many companies with drugs for hepatitis B infection
Consulting or Advisory Role - many companies with drugs for hepatitis B infection
Speakers' Bureau - many companies with drugs for hepatitis B infection
Travel, Accommodations, Expenses - many companies with drugs for hepatitis B infection
 
Xiuhui Li
No Relationships to Disclose
 
Shanzhi Gu
No Relationships to Disclose
 
Chenghai Liu
No Relationships to Disclose
 
Long-Bin Jeng
No Relationships to Disclose
 
Chia Jui Yen
No Relationships to Disclose
 
Calvin Pan
No Relationships to Disclose
 
San-Chi Chen
No Relationships to Disclose
 
Jason Hsieh
No Relationships to Disclose
 
M Wasif Saif
Consulting or Advisory Role - US WorldMeds
Research Funding - Amal Therapeutics; BeiGene; Genentech; GlaxoSmithKline; IDEAYA Biosciences; OBI Pharma; SpringWorks Therapeutics; Yiviva
Patents, Royalties, Other Intellectual Property - UpToDate
 
Shwu-Huey Liu
Employment - Yiviva
Leadership - Yiviva
Stock and Other Ownership Interests - Yiviva
Patents, Royalties, Other Intellectual Property - Co-Inventor of YIV-906
 
Fangyong Li
Consulting or Advisory Role - Yiviva
 
Wing Lam
Consulting or Advisory Role - Yiviva
Patents, Royalties, Other Intellectual Property - Yiv-906
 
Edward Chu
No Relationships to Disclose
 
Yung-Chi Cheng
Leadership - Yiviva (I)
Stock and Other Ownership Interests - Yiviva; Yiviva (I)
Research Funding - Yiviva (Inst)
Patents, Royalties, Other Intellectual Property - YIV-906